Evaluation of Intravenous Dalbavancin for Peritonitis

Terminated

• Conditions: Peritonitis; Peritonitis Bacterial

• Registration Number: NCT04624451
• Lead Sponsor: University of Colorado, Denver

Brief Summary

This study evaluates the use of Dalbavancin 1500 mg IV x 1 dose for treating patients with gram positive peritonitis in patients requiring peritoneal dialysis.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-06-01
• Study First Submitted: 2020-07-09
• Study First Submitted QC: 2020-11-05
• Study First Posted: 2020-11-10
• Primary Completion: 2023-12-31
• Study Completion: 2024-01-31
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-07
• Last Update Posted: 2024-05-09

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

Patients > 18 years of age actively receiving peritoneal dialysis diagnosed with a gram + peritonitis determined to be a good candidate for dalbavancin treatment by the attending nephrology attending.

Read More

Exclusion Criteria

Patients with contraindications to dalbavancin therapy

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical cure	28 days	resolution of signs and symptoms (e.g. abdominal pain), bacterial eradication, reduction in clinical markers (e.g. peritoneal fluid findings, CRP, etc), and return of peritoneal dialysis functionality

Secondary Outcome Measures

Name	Time	Method
Treatment emergent adverse events	28 days	Occurrence of any adverse events

Trial Locations

Locations (1)

University of Colorado Hospital; 🇺🇸 Aurora, California, United States